EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE

The technique of accelerator mass spectrometry (AMS) was validated successfully and used to study the pharmacokinetics and disposition in dogs of a preclinical drug candidate (7-deaza-2'-C-methyl-adenosine; Compound A), after oral and intravenous administration. The primary objective of this study was to examine whether Compound A displayed linear kinetics across subpharmacological (microdose) and pharmacological dose ranges in an animal model, before initiation of a human microdose study. The AMS-derived disposition properties of Compound A were comparable to data obtained via conventional techniques such as liquid chromatography-tandem mass spectrometry and liquid scintillation counting analyses. Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103%). Currently, there are no published comparisons of the kinetics of a pharmaceutical compound at pharmacological versus subpharmacological doses using microdosing strategies. The present study thus provides the first description of the full pharmacokinetic profile of a drug candidate assessed under these two dosing regimens. The data demonstrated that the pharmacokinetic properties of Compound A following dosing at 0.02 mg/kg were similar to those at 1 mg/kg, indicating that in the case of Compound A, the pharmacokinetics in the dog appear to be linear across this 50-fold dose range. Moreover, the exceptional sensitivity of AMS provided a pharmacokinetic profile of Compound A, even after a microdose, which revealed aspects of the disposition of this agent that were inaccessible by conventional techniques.

[1]  R. C. Garner,et al.  A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. , 2000, Journal of pharmaceutical and biomedical analysis.

[2]  R. Colin Garner,et al.  Big physics, small doses: the use of AMS and PET in human microdosing of development drugs , 2003, Nature Reviews Drug Discovery.

[3]  R. C. Garner,et al.  Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. , 1999, Rapid communications in mass spectrometry : RCM.

[4]  Haifang Wang,et al.  Binding of nitrobenzene to hepatic DNA and hemoglobin at low doses in mice. , 2003, Toxicology letters.

[5]  P. Schneider,et al.  Intrinsic erythrocyte labeling and attomole pharmacokinetic tracing of 14C-labeled folic acid with accelerator mass spectrometry. , 1999, Analytical biochemistry.

[6]  R. C. Garner,et al.  Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement. , 2000, Current drug metabolism.

[7]  K. Turteltaub,et al.  Dose-response studies of MeIQx in rat liver and liver DNA at low doses. , 1995, Carcinogenesis.

[8]  K. Turteltaub,et al.  MeIQx-DNA adduct formation in rodent and human tissues at low doses. , 1997, Mutation research.

[9]  J. Southon,et al.  Vesuvius/Avellino, one possible source of seventeenth century BC climatic disturbances , 1990, Nature.

[10]  R. C. Garner,et al.  Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry , 2004, Analytical and bioanalytical chemistry.

[11]  L. Bailey,et al.  Kinetic model of folate metabolism in nonpregnant women consuming [2H2]folic acid: isotopic labeling of urinary folate and the catabolite para-acetamidobenzoylglutamate indicates slow, intake-dependent, turnover of folate pools. , 1998, The Journal of nutrition.

[12]  P. Schneider,et al.  Long-term kinetic study of beta-carotene, using accelerator mass spectrometry in an adult volunteer. , 2000, Journal of lipid research.

[13]  Giovanni Migliaccio,et al.  A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties , 2004, Antimicrobial Agents and Chemotherapy.

[14]  Edwards,et al.  Extremely Large Variations of Atmospheric 14C Concentration During the Last Glacial Period , 2001, Science.

[15]  K. Turteltaub,et al.  Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. , 2000, Current pharmaceutical design.

[16]  J. Overpeck,et al.  Synchronous radiocarbon and climate shifts during the last deglaciation. , 2000, Science.

[17]  K. Turteltaub,et al.  Attomole quantitation of protein separations with accelerator mass spectrometry , 2001, Electrophoresis.

[18]  Graham F. Peaslee,et al.  A new accelerator mass spectrometry system for -quantification of biochemical samples , 2002 .

[19]  G. Raisbeck,et al.  Use of 129I and 137Cs in soils for the estimation of 131I deposition in Belarus as a result of the Chernobyl accident. , 2002, Journal of environmental radioactivity.

[20]  P. H. Stewart,et al.  Tips and traps in the 14C Bio-AMS preparation laboratory (WSam 7) , 1999 .

[21]  J. Vogel.  Rapid Production of Graphite Without Contamination for Biomedical AMS , 1992, Radiocarbon.

[22]  J. Ayrton,et al.  Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  L. Fifield,et al.  Measurement of 237Np in environmental water samples by accelerator mass spectrometry. , 2001, The Analyst.

[24]  P. Pettitt,et al.  Direct radiocarbon dates for Vindija G(1) and Velika Pecína late Pleistocene hominid remains. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Turteltaub,et al.  DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  A. Clifford,et al.  Absorption and retinol equivalence of beta-carotene in humans is influenced by dietary vitamin A intake. , 2003, Journal of lipid research.

[27]  R C Garner,et al.  A preliminary evaluation of accelerator mass spectrometry in the biomedical field. , 1997, Journal of pharmaceutical and biomedical analysis.

[28]  Graham Bench,et al.  A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. , 2003, Analytical chemistry.

[29]  J. Southon,et al.  Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R C Garner,et al.  Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[31]  M. Liebman,et al.  Biomarkers of bone health appropriate for evaluating functional foods designed to reduce risk of osteoporosis. , 2002, The British journal of nutrition.

[32]  C. Haynes,et al.  Holocene age of the Yuha burial: direct radiocarbon determinations by accelerator mass spectrometry , 1984, Nature.